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This study demonstrated that 88 % of untreated sys-
temic lupus erythematosus patients with clinical renal 
clisease displa yed the deposition of immunoglobulin and 
complement at the dermal epidermal junction of the 
noninvolved light exposed extensor surface of the upper 
1/:1 of the forearm (P < 0.005) (positive lupus band test). 
Eighty-five percent of these untreated systemic lupus 
erythematosus patients with anti-deoxyribonucleic acid 
antibodies (native and/or single stranded) (P < 0.001) 
and 96 % of systemic lupus erythematosus patients with 
hypocomplementemia had a positive lupus band test (P 
< 0.001). 
Those systemic lupus erythematosus patients with a 
negative lupus band test or a positive lupus band test 
composed of pure lgM had a decreased incidence of renal 
disease, serum hypocomplementemia and anti-DNA 
antibodies. Their sera, however, frequently contained 
antibodies directed against nuclear ribonuclear protein 
or against the cytoplasmic non-nucleic acid glycoprotein 
termed Ro. 
On the contrary, 85 % of systemic lupus erythematosus 
patients with a positive lupus band test composed solely 
or in part of IgG, had anti-DNA antibodies (P < 0.001). 
Their sera also frequently contained anti-Sm antibodies. 
The lupus band test was found to be dynamic. In gen-
eral, the appearance as well as the disappearance or the 
marked decrease in intensity and complexity of a posi-
tive lupus band test was found to correlate with disease 
exacerbation, remission and the appearance and disap-
pearance of DNA antibodies and serum hypocomplemen-
temia. 
The value of the lupus band test (LBT) in the evaluation of 
systemic lupus erythematosus (SLE) patients is presently very 
controversial. Pohle and Tuffanelli and Burnham and Fine 
s uggested that the LBT may have prognostic significance relat-
ing to the presence or absence of renal disease [2, 3). The latter 
group, employing light-protected skin from the forearm, noted 
a 3-fold increase in clinical renal disease among LBT positive 
patients. In addition, LBT positive patients demonstrated a 3-
fold increase in a peripheral (shaggy) antinuclear antibody 
pattern (a pattern associated with anti-nDNA antibodies) and 
a 4-fold increase in serum hypocomplementemia. 
Gilliam et al extended and amplified these findings employing 
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skin biopsies from the light protected volar aspect of the upper 
forearm [ 4). These authors reported a 55% incidence of a+ LBT 
in SLE patients. More important, they noted that 70% of 
patients with clinical renal disease had a + LBT. Also, approx-
imately 90% of these patients with anti-native DNA antibodies 
and low serum complement had a +LBT. 
Other studies, however , by Caperton, Bean, and . Dick [5], 
Grossman, Ca.llerame, and Condemi [6], Schrager and Rothfield 
[7], Wertheimer and Barlin [8], and most recently Morris et al 
[9] failed to note a statistically significant relationship between 
the + LBT and the presence of clinical renal disease. 
This report presents data of a 5112 yr study employing the skin 
fi·om the light-exposed extensor surface of the upper \1:1 of the 
forearm of untreated SLE patients which demonstrates a high 
correlation between the presence of renal disease, hypocomple-
mentemia, anti-DNA antibodies and skin immunoglobulin and 
complement deposition. 
MATERIALS AND METHODS 
Sixty-two untreated patients satisfying at least 4 of the American 
Rheumatism-Association's (ARA) preliminary criteria for the diagnosis 
of SLE were admitted to this study [10]. Over 80% of t hese patients 
have been followed by the authors with at least quar terly physical and 
laboratory examinat ions. The rema ining patients have been seen at 
least once a nd their clinical charts extensively reviewed for evidence 
relevant to the ARA preliminary criteria for t he diagnosis of SLE. 
Kidney biopsies were performed employing standard percutaneous 
techniques on 22 of these SLE patients having evidence of renal disease 
(defined by the persistence of proteinw-ia on 2 or more occasions, 
te lescopic urinary sediment, greater than 250 mg proteinur ia for 24 lu·, 
Abbreviations: 
C'fix ssDNA antibodies: Complement fixing ant ibodies against 
denatured DNA (single-stranded DNA) (measured by a micro-
complement fixation assay). 
CH 50: Term employed to designate total hemolytic serum com-
plement activity. The term means complement hemolytic activity 
50%. 
CTE: Calf thymic extract 
HLE: human liver extract 
La antibodies: Ant ibodies against a cytoplasmic ribonucleoprotein 
macromolecule identical to the B a nt igen in Sjogren's Syndrome 
(SSB) 1) . 
LBT: Lupus band test-In this paper the skin biopsy was taken 
from the noninvolved extensor surface of the upper 11J of the 
forearm. 
nDNA ant ibodies: Antibodies against native deoxyribonucleic acid 
(double stranded DNA) . 
nRNP antibodies: Antibodies against nuclear ribonucleic ac id 
protein. 
Precipitating antibody systems: Ant ibody systems demonstrated 
by the format ion of precipit ins in agar or other support media. 
Ro ant ibodies: Antibodies against a cytoplasmic nonnucleic acid 
macromolecule-Ident ical to the A antigen in Sjogren's Syndrome 
(SSA) (1) . 
Sm ant ibodies: Antibodies against a nonnucleic acid nuclear mac-
romolecule. 
ssDNA antibodies: Ant ibodies against single-stra nded DNA (mea-
sured by a counterimmunoelectrophoresis technique). 
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BUN greater than 30, or creatinine greater than 1.5 mg/ml). All but 2 
patients demonstrated renal abnormalities for greater than 2 mo. The 
kidney specimens were sectioned into 3 parts, one fragment was fixed 
in 10% buffered formalin and embedded in paraffin. Sections were 
stained with hematoxylin and eosin (H & E), periodic acid schift (PAS) 
reagent, silver methionine (Jones) and masson trichrome. The second 
portion of the specimen was first fixed in a mixture of paraformaldehyde 
gluteraldehyde, then osmium tetraoxide and finally embedded in epson 
812 [11). Sections cut at 1 fl thickness were stained with toludine blue 
and examined by light microscopy. Sections for electromicroscopy were 
cut with an LBK ultratome (LI<B Instruments, Inc., Rockville, MD) 
and examined with a Siemens 101 electron-microscope (Siemens Cor-
poration, Medical Industrial Div., Idelin, NY). The pathologic lesions 
were classified as focal proliferative glomerulonephritis, diffuse prolif-
erative glomerulonephritis and membranoglomerulonephritis [12). The 
third portion of the specimen was snap frozen in liquid nitrogen, 
mounted in liquid tissue embedding medium (O.C.T. Ames) and stored 
at -70°C. Four micron sections were cut in a cryostat (A.O. Cryocut, 
American Optical Corp., Scientific Instrument Div., Buffalo, NY) and 
air dried. The immunofluorescent staining of these specimens was 
performed employing fluorescein conjugated rabbit anti human lgA, 
lgM, lgG, IgE and C3 antisera as described in a previous publication 
[13). 
Skin biopsies were taken from the ultraviolet light-exposed nonin-
volved surface of the upper 1/.1 of the extensor forearm. These biopsies 
were performed employing a 4-mm punch biopsy, 1% xylocaine with 
epinephrine and aseptic technique. These specimens were either placed 
in saline impregnated gauze or transport media [14]. The biopsies were 
then mounted il) O.C.T., snap frozen, stored at -70°C and sectioned 4 
fl thick in a cryostat. Direct immunofluorescent staining techniques 
were employed as previously described. The skin sections were stained 
with fluorescein conjugated antisera to IgA, lgM, IgG, IgE and C3 as 
previously described [15]. All antisera were monospecific as judged by 
gel double diffusion and immunoelectrophoresis. Blocking experiments 
employing unlabelled antisera were performed and demonstrated ap-
propriate blocking of staining. 
Skin biopsies were performed when the patients were initially seen 
and at intervals of 6 mo to 1 hr. Approximately 130 biopsies have been 
performed on these patients. 
The patients have all been examined serologically for (1) antinuclear 
antibody employing standard immunofluorescent techniques with 
mouse liver as a substrate and fluorescein conjugated rabbit ant ihuman 
globulin; (2) precipitating antibody systems against nuclear and cyto-
plasmic RNA (nRNP and La (SSB) respectively) [16, 17]; the nonnu-
cleic acid cytoplasmic component Ro (SSA) (18]; and the nuclear non 
nucleic acid component Sm (19] employing gel double diffusion with 
reference sera, calf thymic extract (CTE) and human liver extract 
(HLE) as previously described [16]; (3) complement fixing antisingle 
stranded DNA antibodies employing a microcomplement fixation assay 
and single-stranded DNA as previously described [1 6]; (4) antisingle 
stranded and antinative DNA antibodies were also assayed by counter 
immunoelectrophoresis, employing a modification of the technique by 
Johnson, Edmonds, and Holborow [20). Specifically, 10 X 8 inch pho-
tographic plates were layered with 15 cc of 1% agarose in barbital buffer 
pH 8.2 and 2 parallel rows of 3-mm holes, 6 mm apart, were punched 
in the agar. Twenty microliters of decomplemented (heated 56°C for 
30 min) test serum were placed in the anodal wells a nd the plates 
electrophoresed for 15 min at 25 rna. Twenty microliters of DNA (2.5 
p.g/ml) were then placed in the cathodal wells and the plates electro-
phoresed for a second time (40 min) . The plates were examined im-
mediately upon comple tion of elec trophoresis and at 24 hr for a precip-
itin reaction. 
To insure the native DNA preparations were free of single stranded 
DNA contamination, DNA was incubated with S1 nuclease (Sigma) at 
37° (1 unit of S1 nuclease/microgram of DNA) in a pH 4.6 acetate 
buffer for 20 min. At the end of that time the pH was brought to 7.2 
with solid trisma base. The DNA was then dialyzed against several 
changes of phosphate buffer (pH 7.4) for 24 hr before being employed 
in the test. 
Single-stranded DNA was prepared by heating native DNA (Sigma) 
in a 100°C water bath for 10 min and immersing in an ice bath. 
Specificity of the precipitin reaction for native DNA was determined 
by digesting the DNA solution with DNAase (Sigma, 5 mg/ml/hr at 
37°C, stopping the reaction by rendering the solution .01 M with EDTA) 
and repeating the counter immunoelectrophoresis. 
(5) Antinative DNA antibodies were assayed employing standru·d 
immunofluorescent techniques and Crithidea luciliae as a substrate for 
native DNA as previously described by Aru·den, deGroot, and Feltkamp 
[21]. The patients' sera were assayed in the Crithidea test at 1-2, I-10, 
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and 1-20 dilutions. All sera which gave negative results at these 
dilutions were then incubated for 1 hr at 37° with DNAase (5 mg/ml; 
Sigma). The reaction was stopped by rendering the solution .01 M with 
ethylenediamine tetra-acetate (EDTA). These DNAase digested sera 
were then tested at 1-2 and 1-20 dilutions. As a control, to rule out the 
possibility that the DNAase in the digested serum denatured the DNA 
of the Crithidea luciliae kinetoplast, known lupus sera containing only 
single stranded DNA antibodies were incubated with DNAase with 1 
hr at 37°C then rendered .01 M with EDTA. These sera were then 
layered over the Crith idea organisms and incubated for 30 min at room 
temperature and stained with the fluorescein conjugated rabbit anti-
whole globulin serum. These specimens failed to produce positive 
staining of the Crithidea, indicating that the DNAase in the technique 
employed to digest the patients' serum failed to denature the native 
DNA in the Crithidea kinetoplast. 
Total hemolytic serum complement (CH50) was determined employ-
ing a modification of the technique by Mayer (22]. ·' 
Statistical analysis was performed on these patients employing Chi-
analysis with Yates correction. 
RESULTS 
Clinical Studies 
Incidence: Forty-two of 62 (67%) untreated SLE patients 
demonstrated a positive lupus band test on the uninvolved 
light-exposed extensor surface of the upper 1/a of the forearm. 
Specificity: To date, we have performed over 600 biopsies on 
normal-appearing skin of the upper lj3 of the extensor forearm 
on approximately an additional 400 individuals, including 100 
patients without skin disease; 80 with bullous pemphigoid; 23 
with pemphigus; 22 with dermatitis h erpetiformis; 18 with 
cicatricial pemphigoid; 5 with herpes gestationis; 40 with DLE; 
20 with vasculitis; 35 rheumatoid and arthritic patients; approx-
imately 150 patients with such skin diseases as atopic eczema, 
scleroderma, dermatomyositis, lichen planus, porphyria cuta-
nea tarda, psoriasis and erythema multiforme. In only 4 in-
stances have we found deposition of immunoglobulins identical 
to that found in SLE. In these 4 instances, however, we were 
unable to demonstrate serological or clinical features of SLE or 
evidence of other skin diseases known to be associated with 
immunoglobulin and complement deposition along the skin 
BMZ (i.e., pemphigoid, d ermatitis herpetiformis, etc). These 4 
patients had erythema elevatum diutinum, a hypocomplemen-
temic urticaria-like vasculitis, chronic active hepatitis and an 
ill-defined hereditary connective tissue disorder. 
Relationship of Severity of Clinical Diseases: The relation-
ship between a + LBT and clinical features of the lupus process 
are presented in Table I. Note the striking difference in the 
inc idence of a +LBT in patients with clinical renal disease (P 
< 0.005). There was no relationship between the presence of a 
+ LBT -and the antinuclear antibody titer. Thirty of 62 (48 %) 
had cutaneous manifestations of lupus. These cutaneous man-
ifestations included classic photosensitive malar dermatitis, 
scarring alopecia and discoid lupus les ions. Twenty-one of these 
patients (70%) had a +LBT (overall incidence of a +LBT was 
67%). Only one of 42 +LBT patients subsequently developed 
lupus skin lesions at the site of a previous skin biopsy. 
TABLE I. Relationship of clinical features to presence of a positive 
lupus band test 
Clinical status Positive % P-value skin test 
Clinical renal disease 26 patients 23 88 0.005" 
Central nervous system 11 patients 6 55 N.S. 
Coombs+ hemolytic anemia 10 patients 8 80 N.S. 
Arthritis and arthralgias 55 patients 36 65 N.S. 
Skin manifestations 30 patients 21 70 N.S. 
Mild disease (no CNS or renal) 25 pa- 13 52 N.S. 
tients 
Nonrenal 36 patients 18 50 N.S. 
" P-value derived from a comparison of the incidence of a positive 
lupus band test in SLE patients having clinical renal disease with the 
incidence of a positive lupus band test in those SLE patients without 
renal disease. 
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Relationship of positive LBT to Severity of Renal Lesions: 
The relationship of a + LBT to the type of glom~rular ~atho~ogy 
is presented in Table II. Note, 91 % of the pat1ents w1th histo-
logic evidence of renal lupus had a +LBT. H~wever, note the 
lack of correlation of a + LBT to the seventy of the re~al 
glomerular lupus process. In our_ series ~ + LBT ;;as f?u~,d w1th 
even greater frequency in pat1ents w1th the bemgn focal 
glomerular lesions. . . . 
Relationship of class of Ig depo_sLtw': m a +f:B! . and 
presence of renal disease: Th~ _relatwnsh1p of the mdividual 
class of immunoglobulin depos1t1on to the presen~e or absence 
of renal disease is presented in Table III. A negat1ve LBT was 
associated with a low incidence of clinical renal disease as was 
a +LBT with pme IgM. However, the presence oflg~ alone_ or 
together with other Ig classes in a +LBT was associated with 
a high incidence of clinical renal disease (16 of 27 patients) (P 
< 0.01). . . . 
Relationship of Ig deposition in a +LBT to Ig deposLtwn m 
glomeruli: Complete concordance between the individual class 
of Ig deposition of the skin and kidney occurred 50% of the 
time. Most important, however, was our fmding that the co~­
plexity of Ig deposition in the +LBT was n?t relat~d to s~venty 
of the glomerular lesion. In other words 1t was 1mposs1ble to 
predict the severity of the renal glomerular lesion by the types 
of Ig present in the LBT. For example, a LBT composed of IgA, 
IgG, lgM could be found in the setti~~ of focal as well as 
membranoproliferative glomerulonephntJs. 
Fate of +LBT following therapy: The fat~ o~ the +_LBT 
following prolonged therapy has been followed m mn~ patients. 
A total of 40 biopsies have been taken on 9 SLE pat1ents. The 
+ LBT in these 9 patients was composed of lgG_ and ~ther 
iinmunoglobulins. In all 9 patients the LBT has e1ther disap-
peared or has manifested dimi_n~shed intensity of_ staining a~d 
a lesser complexity of Ig depositiOn (completely disappear~d m 
5, faint IgG remaining in 4). In all but 2, _therapy has consisted 
of prednisone, 30-50 mg/day. In one patient cytoxan, 100 mg/ 
day, and in another chlorambucil, 2 mg/day, were added to 
daily prednisone. Significant changes in the LBT were generally 
not noted for at least 4-6 mo after institution of therapy. The 
disappearance or the striking decrease in the intensity of stai~­
ing of the LBT was associated with a marked improvement m 
the patients' clinical status (including a disappearance of pro-
teinuria in 4 of 6 patients). 
Relationship of a change in LBT to clinical disease activity: 
We noted 6 patients who have demonstrated a conversion froi? 
a negative to a + LBT or whose + LBT has upon repeat exami-
nation exhibited additional classes of immunoglobulin deposi-
tion. In 4 of these patients, there was clinical exacerbation or 
deterioration with the appearance of renal disease correspond-
ing to the change in the LBT. In only one patient was a change 
in the LBT unassociated with a perceptible clinical change. In 
one patient we noted that the appearance of Ig deposition in 
the skin correlated with appearance and disappearance of evi-
dence of clinical renal disease. 
Correlation of LBT with serum antibodies and serum com-
plement levels: In Table IV the relationship between the pres-
ence of anti-n and ssDNA antibodies, low serum complement 
and a +LBT are presented. Note the high incidence of +LBT 
with the presence of low serum complement (P < 0.001) and 
anti ssDNA and anti-nDNA antibodies (P < 0.001). 
TABLE II. Relationship of a positive lupus band test to histologic 
evidence of renal disease 
Renal disease biopsies on 22 pa-
tients 
Focal glomerulonephritis biopsies 
on 11 patients 
Membranous or proliferative glo-
merulonepru·itis biopsies on 11 
patients 
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TABLE III. Relationship of class of antibody deposition in a lupus 
band test to clinical renal disease 








TABLE IV. Relationship of ccmplement fixing Anti-ssDNA and 
Anti-nDNA antibodies and serum hypocomplementemia to a positive 
lupus band test (LET) 
Positive LBT % + P-Value 
C' fixing anti-ssDNA anti- 22 88 <0.01" 
bodies 
25 
No C' fixing anti -ssDNA 20 55 
antibodies" 
36 
Anti-nDNA antibodies 23 92 <0.01" 
25 
No anti-nDNA antibodies 22 58 
38 
Total patients with anti- 35 85 <0.001" 
ssDNA (C' fixing & non C' 
fixing) and/ or anti-nDNA 
41 
Total patients without anti- 7 33 
ssDNA and/ or anti-nDNA 
21 
Low serum complement 27 96 <0.001" 
28 
Normal serum complement 15 45 
33 
"Two patients' sera too anticomplementary to test for C' fixing 
single-stranded DNA antibodies. 
"Comparison of the incidence of a positive lupus band test in 
untreated SLE patients with ssDNA and nDNA antibodies and hypo-
complementemia with the occurrence of a positive lupus band test in 
untreated SLE patients without ssDNA and native DNA antibodies 
and hypocomplementemia. 
There are several interesting observations regarding the re-
lationship of a + LBT to the presence of DNA antibodies. Only 
3 patients demonstrated antibodies to nDNA without the con-
comitant presence of complement fixing antibodies to ssDNA 
as judged by the techniques employed. However, 7 LBT+ SLE 
patients have demonstrated complement fixing antibodies to 
ssDNA on repeated determinations of their sera. Antibodies to 
HDNA, however, have not been detected despite DNAase treat-
ment of these sera (see methods). 
Relationship of Ig class in an LBT with DNA antibodies: 
The relationship of individual immunoglobulin class demon-
strable in a +LBT and serum antibodies is presented in Table 
V. Of the 20 LBT negative patients, only 2 patients had nDNA 
and/or complement fixing ssDNA. Note that with a LBT of 
pure IgG or IgG together with other Ig's there is an increasing 
percentage of patient's having complement fixing antibodies to 
ssDNA as well as antibodies to nDNA and Sm in their serum. 
By contrast, patients with a negative LBT or pure IgM positive 
LBT have a high frequency of antibodies to n-RNP and Ro 
(Table VI). The increased incidence of complement fixing anti-
ssDNA and/or nDNA and anti-Sm antibodies associated with 
an lgG +LBT (23 of 27 patients) compared to their incidence 
in a negative LBT (2 or 20 patients) is significant (P < 0.001). 
Correlation of LBT with serum antibodies and serum com-
plement Levels following therapy: The disappearance or the 
decrease in intensity and complexity of a positive lupus band 
test in 9 SLE patients following therapy was associated with 
the normalization of serum complement and disappearance of 
DNA antibodies. 
Correlation of a change in the LBT with serum antibodies 
and serum complement levels: We have noted 6 patients who 
have demonstrated a conversion from negative to a + LBT or 
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whose + LBT upon repeat testing has exhibited additional 
classes of immunoglobulin deposition. Their serologic data are 
summarized in Table VII. Note the dynamic relationship be-
tween a +LBT and the presence of antibodies to DNA and 
hypocomplementemia. What is apparent from observations of 
these SLE patients is that changes in clinical status and the 
lupus band test are frequently correlated with the appearance 
and disappearance of antibodies to DNA. The ch anges in LBT 
were also generally associated with a change in serum comple-
ment levels. In 3 instances (J.W., P .W., and A.M .) these ch anges 
were associated with the appearance of C' fixing anti-ssDNA 
antibodies in the apparent absence of anti-nDNA antibodies. 
Interestingly, only patient, E.R., did not show an associated 
TABLE V. Relationship of class of antibody depo.sition in. a lupus 
test band (LET) to hypocomplemen.temia and DNA antibodies 
Hypo N &C' C' fix Non C' LBT comple- nDNA fix ssDNA fix mentem ia ssDNA DNA" 
Neg (20)" 3 0 2 0 4 
M alone (13) 4 3' 1 1<1 4 
G alone or 20 2+ 15 6" 1 
+ other Igs (27) 
" Determined by demonstrating anti-ssDNA antibodies by counter 
immunoelectrophoresis in absence of ssDNA antibodies by microcom-
plement fixation assay. 
1
' Number in .parenthesis represents number of patients. 
cOne patient possessed serum to anticomplementary to determine 
C' ftxing ssDNA antibodies. 
" Indicates only C' fixing antibodies to ssDNA detected in mul tiple 
serum samples-no antibodies to nDNA detected. 
Two patients not included in this table had a IgM and C3 +LBT and 
nand C' fix ssDNA antibodies. 
TABLE VI. Relationship of class of antibodies in a lupus band test 
(LET) with precipita ting antibodies (Sm, n.RN P, R o and L a) 
Precipitating antibod ies 
LBT 
Sm nRNP Ro La Unidentified 
Neg (20)" 2 5 4 2 0 
Malone (13) 3 5 5 0 0 
G alone or 9 8 5 2 3 
+ other Igs (27) 
" Number in parenthesis represents a number patients. 
Two patients with a + LBT of lgM and C3 not included on this table 
displayed antibodies 'to Ro in the first instance an unidentified precip-
itating antibody system in the second case. 
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change in serum antibodies. In patient M .T. one can see that 
the appearance, disappearance and reappearance of Ig deposi-
tion in the skin correlated with appearance and disappearance 
of anti DNA antibodies and serum hypocomplementemia. 
DISCUSSION 
Om studies like those of Gilliam et al and Bmnham and Fine 
show that there is a relationship between the presence of a 
+ LBT and the presence of renal disease [3, 4]. This experience 
is not universal. Grossman, Callerame, and Condemi in a small 
series, reported that the incidence of a + LBT was 78% in SLE 
patients with renal disease (statistically not significant) while 
SLE patients without renal disease had a 42% incidence of a 
+LBT (6]. Both Schrager and Rothfield, and Caperton, Bean, 
and Dick did not find any relationship between the presence of 
a + LBT and the existence of renal disease [5, 7]. In both series 
the number of patients studied were small and in Schrager and 
Rothfield's series only 5 cases with active renal disease were 
studied [7]. In Caperton's series the emphasis was on the 
possible correlation of a +LBT with the pathologic type of 
glomerular involvement and the severity of the disease [5). No 
serologic or complement data were presented. The incidence of 
a +LBT in the lupus nephritis patient population was 67%. The 
control group, however, consisted of only 6 SLE patien ts with-
out clinically apparent renal disease. Fom of these SLE patients 
had a +LBT (67%). The 6 "control" patients were described as 
being very sick; all but one of them had life-threatening disease. 
In view of the lack of serologic, complement and renal biopsy 
data and the fact that an immunologically significant insult to 
the kidney may antedate urinary and renal function a bnormal-
ities, it is conceivable that these very sick lupus control patients 
may, indeed, have had subclinical renal disease (23, 24]. OUT 
data, however, like Caperton's indicates there is no correlation 
between complexity of the +LBT and the pathologic type of 
glomerular lesion [5]. 
Wertheimer and Barland and Morris et. al. also failed to note 
a correlation between a positive lupus band test and clinical 
renal disease [8, 9]. These SLE patients were very h eterogenous 
regarding therapy. Many were and had been on prolonged 
steroid and immunosuppressive therapy at the time of the 
initial biopsy. In view of the data presented in this paper and 
that of Gilliam et. al. which demonstrates that prolonged steroid 
and cyclophosphamide therapy influences the incidence of a 
LBT, as well as the clinical renal disease, it is difficult to 
compare their results with ours [ 4). 
TABLE VII. R elationship of a con.uersion. of a n.egatiue to positiue lupus band tesl (LBT) or a change in. intensity of a p ositiue LET to 
serologic data 
Patient Date LBT Anti-DNA Precipitin Serum Ab" complement(' 
M.R. 4-75 M nRNP N 
11-75 A,G,M +(C' fix ssDNA nRNP, Sm ~ 
and nDNA) 
M.T. 1-73 A, G. M, E, C3 +(C' fix ssDNA nRNP ! 
and nDNA) 
5-74 neg N 
1-75 G +(C' fix ssDNA) nRNP ~ 7-75 neg N 
11- 75 neg N 
J.W. 5- 72 neg nRNP, Sm N 
12-74 A, G. M, C3 +(C' fix ssDNA) nRNP, Sm ! 6- 75 G +(C' fix ssDNA) nRNP, Sm ! 12- 75 neg nRNP, Sm N 
P.W. 10-71 M N.T. N.T. N 
7- 72 M.G. +(C' fix ssDNA) Sm, Ro ! 6-74 M Sm,Ro N 
11-75 M Sm, Ro N 
A.M. 1-72 neg Ro N 
3-75 M +(C' fix ssDNA) Ro N 
E.R. 6-72 neg Ro N 
9-75 G Ro N 
"N.T., not tested, N, normal, ! , decreased. 
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This study has demonstrated that a negative or a pure IgM 
LBT is infrequently associated with the presence of clinical 
evidence of renal disease. In contradistinction, those patients 
who have lgG deposition at the dermal-epidermal junction have 
a high incidence of histological and clinical evidence of renal 
disease. Similar data has recently been presented by Penne-
baker, Gilliam, and Ziffm [25]. 
Recent findings in NZB/ NZW mice also indicate that there 
may be a similar relationship between a pure IgM and pure IgG 
LET and severity of lupus disease in these animals. Male and 
young female NZB/NZW mice having a mild lupus disease tend 
to have negative or pure IgM LBT. Older NZB/ NZW female 
mice, however, with active severe lupus disease have an IgG 
positive LBT [25, 27]. 
This study also demonstrates that the deposition of Ig and C 
at the dermal-epidermal junction is dynamic, tending to become 
more intense with increased activity of the lupus process (es-
pecially the renal disease) and tends to disappear with success-
ful control of the disease. 
One observation noted by Schrager and Rothfield, as well as 
demonstrated in this study, is the apparent lack of relationship 
between the immunoglobulin and complement deposition at 
the dermal-epidermal junction and the presence of cutaneous 
manifestations of lupus erythematosus [7]. A + LBT occurred 
with the same frequency in lupus patients with cutaneous 
disease as it did in the overall lupus patient population. Seven 
of 20 LBT negative lupus patients had cutaneous disease . 
This study demonstrates a statistically significant relation-
ship exists between the presence of a + LBT and the presence 
of anti-DNA antibodies and serum hypocomplementemia. Such 
a statistical association has previously been noted by Gilliam et 
al and Grossman et a! [ 4, 6) Gilliam and co-workers noted that 
90% of their SLE patients with nDNA antibodies and hypocom-
plementemia had a +LBT. Grossman's studies reported only 
serum hypocomplementemia and they too noted a statistically 
significant association. 
Our studies extend the previous studies by demonstrating 
that the lupus band test is dynamic tending to disappear with 
disease remission and reappear or to first appear with worsening 
of the clinical disease. Furthermore, the ppearance or disap-
pearance of the lupus band test frequently corresponds to the 
appearance and disappearance of anti-DNA antibodies and 
hypocomplementemia. 
These studies are also unique for they demonstrate a corre-
lation of the +LBT with the presence of C' fixing anti-ssDNA 
antibodies. Of interest is the fact that we have observed several 
SLE patients with clinical renal disease and positive lupus band 
tests who despite repeated serological determinations over a 
period of several years, failed to demonstrate antibodies to 
nDNA but whose serum displayed complement fixing anti-
bodies to ssDNA. Not only have such patients been reported 
previously but glomerular eluates from 3 such SLE patients 
with glomerulonephritis revealed only antibodies to ssDNA 
[28]. This suggests that immune complexes composed of ssDNA 
may play a role in the genesis of the lupus glomerulonephritis 
in some SLE patients. 
This study also demonstrates that those SLE patients pos-
sessing a negative LBT have a very low incidence of anti-nDNA 
and complement fixing ssDNA antibodies. Forty-five percent of 
their sera, however, possessed anti-nRNP and anti-Ro anti-
bodies. 
Those SLE patients possessing a + LBT composed solely of 
IgM also have a low incidence of antibodies to DNA. Their 
serum, however, displayed a 77% incidence of anti nRNP and/ 
or antibodies to Ro. 
In contradistinction, those SLE patients having IgG deposi-
tion at the dermal-epidermal junction either alone or together 
with other classes of lgs have an 85% incidence of antibodies to 
ssDNA and/or nDNA (23 of27 patients). Pennebaker et al and 
Sontheimer and Gilliam have also detected this relationship 
LUPUS BAND TEST 411 
between the class of immunoglobulin present in the positive 
lupus band test and the presence of DNA antibodies [25, 29]. 
The nature · of the IgM deposition in a pure IgM positive 
lupus band test is unknown. We found that an IgM +LBT can 
occur in the absence of detectable serum IgM anti-nDNA 
antibodies (data not shown but experiments performed by 
layering patients sera over Crithidea luciliae (the source of 
nDNA) incubated and then stained with fluorescein conjugated 
anti-human IgM fc specific antisera). Sontheimer and Gilliam 
have also reported this observation [29). Admittedly, however, 
IgM anti-nDNA immune complexes could preferentially stick 
in the skin and/or the lgM anti-DNA antibody concentration 
in the serum be so small as to escape detection by our tech-
niques. 
The question that remains is what is the pathophysiologic 
mechanism responsible for these skin deposits? At present there 
are 2 working hypothesis. One is that the deposition is the 
result of circulating immune complexes. It is hypothesized that 
complexes similar to those deposited in the kidney egress across 
the terminal arterioles in the region of the dermal-epidermal 
junction. 
Alternatively, Gilliam has proposed and we support the hy-
pothesis that these dermal epidermal Ig and C deposits may 
originate under the influence of local factors such as blood 
supply, epidermal proliferation and ultraviolet light exposme 
[30]. It is theorized that epidermal nuclear antigens may be 
released locally following ultraviolet light radiation denatura-
tion with subsequent release of the damaged epidermal nuclear 
DNA following enzymatic cleavage by the endonucleases or 
following epidermal proliferation secondary, for instance, to 
physical trauma. Such epidermal derived DNA then could 
diffuse across the basement membrane and interact with cir-
culating antinuclear antibodies at the dermal epidermal junc-
tion. If true, this hypothesis would explain the apparent higher 
incidence of positive LBT in SLE patients in the light exposed 
than nonlight exposed areas [3, 31]. Indeed, recent work in om 
laboratory has indicated that a striking difference in the inci-
dence of positive lupus band exists between light-exposed and 
unexposed biopsy sites in untreated SLE patients when these 
tests are performed simultaneously [32]. Also, Sontheimer and 
Gilliam have recently published data indicating varying inci-
dences of a positive LBT with the site of biopsy in NZB/NZW 
Fi hybrid mice. They found that biopsies taken from skin sites 
with increased epidermal proliferation (increased DNA synthe-
sis) had a higher incidence of a positive LBT than biopsies of 
skin sites without an increase in epidermal proliferation [33]. 
1'he justification for implicating antibodies with antinuclear 
specificity in the lupus band test deposits rests on 2 reports of 
elution of such antibodies fi·om the uninvolved skin of SLE 
patients [34, 35]. 
Recent intriguing studies, perhaps germane to this latter 
hypothesis, have been presented by Izue, Lambert, and 
Meischer [36). These workers have demonstrated that both n 
and ssDNA have an affinity for collagen present in skin and 
glomerular basement membranes. Thus, the +LBT may, rep-
resent an in vivo binding of DNA antibodies ton and/ or ssDNA 
bound to basement membrane collagen. In essence, then the 
lupus band test may be an in vivo binding test for antibodies to 
DNA. If this is so, and the data presented above supports such 
a hypothesis, then the association of a +LBT with renal disease 
is explainable since a very high percentage of SLE patients with 
anti DNA antibodies develop hypocomplementemia and renal 
disease [37). 
Finally, we believe that a very important variable, in addition 
to the site of biopsy, effecting the incidence of positivity of a 
lupus band test and its relationship to anti-DNA antibodies, 
hypocomplementemia and renal disease is treatment. Modern 
day treatment of SLE patients with steroids and / or immuno-
suppressive agents has produced a <hamatic improvement in 
SLE mortality figures. Successful treatment of SLE patients 
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produces, very frequently, a normalization of serum comple-
ment, disappearance of anti DNA antibodies and proteinuria. 
As has been demonstrated in Gilliam et al 's. and our studies, 
treatment also induces the disappearance of the positive lupus 
band test [ 4]. Therefore, we believe it is impossible to evaluate 
the lupus band test in SLE patients on treatment since the 
treatment produces such drastic changes both in the incidence 
of the positivity of this test as well as the clinical and serologic 
abnormalities with which th e lupus band test is often compared. 
We, further, feel that failure to control this treatment variable 
is the major reason for the discordant findings regarding the 
correlation of a positive lupus band test with clinical renal 
disease previously published in the literature [7, 9). 
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